ArticleFrontiers in cardiovascular medicine2026
Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anthracyclines are highly effective chemotherapeutic agents but are limited by cumulative, dose-dependent cardiotoxicity, leading to strict lifetime exposure thresholds. L-Annamycin is a next-generation liposomal anthracycline designed to preserve antitumor efficacy while reducing cardiotoxicity. Methods: We performed a pooled analysis of cardiac safety data from five sponsor- and investigator-initiated clinical trials evaluating L-Annamycin in acute myelogenous leukemia (AML) and metastatic soft tissue sarcoma (STS). Cardiac monitoring included serial electrocardiograms, cardiac biomarkers (troponin I/T), and transthoracic echocardiography with left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) assessment. All cardiac data were independently evaluated by a cardio-oncology laboratory at the Cleveland Clinic. Results: Ninety patients were included, with paired echocardiographic data available in 78. Median cumulative L-Annamycin dose was 660 mg/m Conclusions: In this pooled analysis of patients with AML and STS, L-Annamycin was not associated with clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline thresholds. These data support continued clinical evaluation of L-Annamycin as a potentially safer anthracycline platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.